Is Long-Acting Injectable Cabotegravir Likely to Expand PrEP Coverage Among MSM in the District of Columbia?
作者信息
Levy Matthew E, Agopian Anya, Magnus Manya, Rawls Anthony, Opoku Jenevieve, Kharfen Michael, Greenberg Alan E, Kuo Irene
机构信息
Department of Epidemiology,Milken Institute School of Public Health at the George Washington University,Washington, DC.
Westat, Rockville, MD.
出版信息
J Acquir Immune Defic Syndr. 2021 Mar 1;86(3):e80-e82. doi: 10.1097/QAI.0000000000002557.
Abstract
摘要
相似文献
1
Is Long-Acting Injectable Cabotegravir Likely to Expand PrEP Coverage Among MSM in the District of Columbia?长效注射用卡博特韦有可能扩大哥伦比亚特区男男性行为者的暴露前预防覆盖范围吗？
J Acquir Immune Defic Syndr. 2021 Mar 1;86(3):e80-e82. doi: 10.1097/QAI.0000000000002557.
2
Potential effectiveness of long-acting injectable pre-exposure prophylaxis for HIV prevention in men who have sex with men: a modelling study.男男性行为人群中长效注射型 HIV 暴露前预防的潜在有效性：一项建模研究。
Lancet HIV. 2018 Sep;5(9):e498-e505. doi: 10.1016/S2352-3018(18)30097-3. Epub 2018 Jun 13.
3
Willingness and preferences for long-acting injectable PrEP among US men who have sex with men: a discrete choice experiment.美国男男性行为者对长效注射用暴露前预防药物的意愿和偏好：一项离散选择实验
BMJ Open. 2024 Apr 22;14(4):e083837. doi: 10.1136/bmjopen-2023-083837.
4
Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial.用于预防HIV的卡博特韦长效注射用混悬液的满意度和可接受性：来自ECLAIR试验的患者观点
HIV Clin Trials. 2018 Aug;19(4):129-138. doi: 10.1080/15284336.2018.1511346. Epub 2018 Nov 16.
5
Long-acting injectable for HIV approved for use in the UK.长效注射用抗艾滋病毒药物在英国获批使用。
Lancet Infect Dis. 2022 Jan;22(1):26. doi: 10.1016/S1473-3099(21)00775-1.
6
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women.卡博特韦用于预防顺性别男性和跨性别女性中的 HIV。
N Engl J Med. 2021 Aug 12;385(7):595-608. doi: 10.1056/NEJMoa2101016.
7
High Propensity to Switch to Long-acting Injectable HIV PrEP with Cabotegravir in a Cohort of Oral PrEP Experienced Men who Have Sex with Men in Italy.在意大利，接受过口服 HIV 预防药物（PrEP）的男男性行为者队列中，卡替拉韦长效注射制剂具有较高的转换意愿。
AIDS Behav. 2024 Mar;28(3):907-911. doi: 10.1007/s10461-023-04197-8. Epub 2023 Oct 4.
8
Intention and preference to use long-acting injectable PrEP among MSM in the Netherlands: a diffusion of innovation approach.意向和偏好使用长效注射型 PrEP 预防男男性行为者中的 HIV 感染：创新扩散方法。
AIDS Care. 2024 Jul;36(sup1):89-100. doi: 10.1080/09540121.2024.2307378. Epub 2024 May 7.
9
Lessons for Patient Education Around Long-Acting Injectable PrEP: Findings from a Mixed-Method Study of Phase II Trial Participants.长效注射型 HIV 预防药物（PrEP）患者教育的启示：来自 II 期临床试验参与者混合方法研究的结果。
AIDS Behav. 2018 Apr;22(4):1209-1216. doi: 10.1007/s10461-017-1871-x.
10
Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis.卡博特韦长效注射混悬剂：用于 HIV-1 暴露前预防的综述。
Drugs. 2022 Sep;82(14):1489-1498. doi: 10.1007/s40265-022-01791-3. Epub 2022 Oct 18.
引用本文的文献
1
Willingness to Use Long-Acting Injectable Pre-Exposure Prophylaxis among Adolescent Girls and Young Women in Kampala, Uganda.乌干达坎帕拉少女和年轻女性使用长效注射式暴露前预防药物的意愿
AIDS Behav. 2025 May;29(5):1458-1469. doi: 10.1007/s10461-025-04616-y. Epub 2025 Jan 30.
2
Preferences for Starting Daily, On-Demand, and Long-Acting Injectable HIV Preexposure Prophylaxis Among Men Who Have Sex With Men in the United States (2021-2022): Nationwide Online Cross-Sectional Study.美国男男性行为者对每日、按需和长效注射型 HIV 暴露前预防用药的偏好（2021-2022 年）：全国范围在线横断面研究。
JMIR Public Health Surveill. 2024 Nov 13;10:e62801. doi: 10.2196/62801.
3
Willingness to Use Long-Acting Injectable PrEP Among PrEP Naïve Black and Hispanic Sexual Gender Minority Persons.愿意使用长效注射型 PrEP 的 PrEP 初治黑人及西班牙裔性少数群体。
AIDS Behav. 2024 Jun;28(6):2166-2174. doi: 10.1007/s10461-024-04314-1. Epub 2024 Mar 25.
4
Willingness to take long-acting injectable pre-exposure prophylaxis among men who have sex with men who participated in the CROPrEP study: a cross-sectional online study.在参与 CROPrEP 研究的男男性行为者中，使用长效注射型暴露前预防的意愿：一项横断面在线研究。
BMC Public Health. 2023 Dec 13;23(1):2494. doi: 10.1186/s12889-023-17325-9.
5
Variation in Preferences for Long-Acting Injectable Pre-Exposure Prophylaxis Among US Men Who Have Sex with Men: A Latent Class Analysis.美国男男性行为者对长效注射型暴露前预防用药偏好的差异：潜在类别分析。
AIDS Patient Care STDS. 2023 Oct;37(10):495-503. doi: 10.1089/apc.2023.0109.
6
Injectable Pre-Exposure Prophylaxis for HIV Prevention: Perspectives on the Benefits and Barriers from Gay, Bisexual, and Queer Men and Health System Stakeholders in Ontario, Canada.注射用 HIV 预防暴露前预防：安大略省男同性恋、双性恋和酷儿人群及卫生系统利益相关者对其益处和障碍的看法。
AIDS Patient Care STDS. 2023 Jun;37(6):306-315. doi: 10.1089/apc.2023.0034. Epub 2023 May 16.
7
Willingness to use and preferences for long-acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021-2022: cross-sectional study.2021-2022 年美国南部性少数群体和性别少数群体对长效注射型 PrEP 的使用意愿和偏好：横断面研究。
J Int AIDS Soc. 2023 Mar;26(3):e26077. doi: 10.1002/jia2.26077.
8
Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis.基于 HPTN 083 和 HPTN 084 试验的南非长效注射型卡替拉韦与口服暴露前预防的相对成本效益：模型经济评估和阈值分析。
Lancet HIV. 2022 Dec;9(12):e857-e867. doi: 10.1016/S2352-3018(22)00251-X. Epub 2022 Nov 7.
9
Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis.卡博特韦长效注射混悬剂：用于 HIV-1 暴露前预防的综述。
Drugs. 2022 Sep;82(14):1489-1498. doi: 10.1007/s40265-022-01791-3. Epub 2022 Oct 18.
10
Barriers and Facilitators to HIV Pre-Exposure Prophylaxis Uptake Among Men Who have Sex with Men Who Use Stimulants: A Qualitative Study.男男性行为者中使用兴奋剂者接受 HIV 暴露前预防的障碍和促进因素：一项定性研究。
AIDS Behav. 2022 Sep;26(9):3016-3028. doi: 10.1007/s10461-022-03633-5. Epub 2022 Mar 18.
Zotero 插件